Endo International has released PREVDUO, a pre-filled syringe that combines neostigmine methylsulfate and glycopyrrolate injection. This product is the first and only FDA-approved neostigmine-glycopyrrolate combination available in the US. The two ingredients have both been approved as single active ingredient drug products. By eliminating the need for two discrete syringe preparations and administrations, hospitals and healthcare providers can increase efficiency. Endo's Par Sterile Products business will be distributing PREVDUO exclusively in the US after executing an agreement with Slayback Pharma earlier this year.
The new product is expected to streamline operations for hospitals by reducing waste and costs, optimizing convenience and workflow, and reducing the chance of preparation errors - all of which support quality patient care. Neostigmine is always administered in conjunction with glycopyrrolate; until now, its administration required two syringes.
Endo International plc is a specialty pharmaceutical company committed to delivering quality life-enhancing therapies. Its decades of proven success come from passionate team members around the globe collaborating to bring treatments forward.
Keywords: Endo International, PREVDUO, pre-filled syringe, neostigmine methylsulfate, glycopyrrolate